HC Wainwright Forecasts Stronger Earnings for ImmunityBio

ImmunityBio, Inc. (NASDAQ:IBRX) – Analysts at HC Wainwright raised their FY2030 earnings estimates for ImmunityBio in a research note issued to investors on Monday, January 26th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn $0.83 per share for the year, up from their previous estimate of $0.68. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share.

IBRX has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Piper Sandler lifted their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. D. Boral Capital reiterated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a report on Tuesday, January 20th. BTIG Research raised their price objective on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Finally, Jefferies Financial Group upped their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, ImmunityBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $5.91 on Wednesday. The company has a market capitalization of $5.82 billion, a P/E ratio of -14.41 and a beta of 0.03. The business has a 50-day moving average of $3.05 and a two-hundred day moving average of $2.67. ImmunityBio has a 1 year low of $1.83 and a 1 year high of $8.28.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $32.06 million during the quarter, compared to the consensus estimate of $31.88 million.

Insider Activity

In related news, Director Barry J. Simon sold 151,967 shares of ImmunityBio stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total value of $1,094,162.40. Following the sale, the director owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christobel Selecky sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total value of $187,750.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 226,967 shares of company stock worth $1,531,912 over the last three months. Insiders own 69.48% of the company’s stock.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently made changes to their positions in IBRX. AQR Capital Management LLC grew its stake in shares of ImmunityBio by 193.4% in the first quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock valued at $134,000 after buying an additional 29,297 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in ImmunityBio during the second quarter worth $43,000. Vigilare Wealth Management acquired a new stake in ImmunityBio in the second quarter valued at $31,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of ImmunityBio by 39.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,095 shares of the company’s stock valued at $90,000 after acquiring an additional 9,663 shares during the period. Finally, Grimes & Company Inc. increased its stake in shares of ImmunityBio by 484.4% during the 2nd quarter. Grimes & Company Inc. now owns 58,436 shares of the company’s stock worth $154,000 after purchasing an additional 48,436 shares during the last quarter. Institutional investors own 8.58% of the company’s stock.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: HC Wainwright raised multi-year EPS forecasts (FY2027–FY2030) and keeps a “Buy” rating with a $10 price target, signaling improved earnings expectations that could support upside over the medium term. ImmunityBio (NASDAQ:IBRX) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Traders appear to be taking profits after a roughly two-week rally, which produced a short-term pullback in the share price rather than a fundamental reversal; this is a common swing-trading reaction after concentrated gains. ImmunityBio (IBRX) sheds 4% on profit-taking after 14-day run
• Neutral Sentiment: Liquidity and technicals show heavy recent trading and a wide 52-week range; elevated volume and a rebound off the low can amplify moves in either direction, increasing volatility risk for short-term holders. MarketBeat IBRX quote and metrics
• Negative Sentiment: Pomerantz LLP issued an investor alert announcing an investigation into ImmunityBio, introducing potential litigation and governance risk that could weigh on sentiment and increase downside pressure if the inquiry escalates. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. – IBRX

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.